vTv Therapeutics Inc(VTVT) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 52 full-time employees. The firm is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Current Price

$2.43

RSI

28.204

Beta:

-1.815223

February 24, 2021
155K
-2.2M

2210.667 %
1292.083 %
123.351 %
36.413 %

$5,722,000
$1,225,000
$9,156,000
$-2,790,000
$238,000
$519,000
367.102 %
-647.429 %
130.472 %
-108.530 %
-118.067 %

$-10,399,000
$-12,944,000
$-7,711,000
$-15,344,000
$-55,353,000
$-41,107,000
24.474 %
-40.428 %
98.988 %
260.747 %
-25.737 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.